Entera Bio Ltd. is a clinical stage biopharmaceutical company focused on developing oral tablet formulations of peptides and protein replacement therapies. The company uses its proprietary N Tab platform to stabilize large hydrophilic peptides in the gastrointestinal tract and promote their absorption into the bloodstream. Its pipeline includes candidates for osteoporosis hypoparathyroidism obesity and short bowel syndrome. The lead product EB613 is an oral form of parathyroid hormone 1 34 intended to treat postmenopausal osteoporosis. EB613 has been administered to a total of 270 study participants including postmenopausal women with low bone density healthy volunteers and patients with hypoparathyroidism. In a Phase 2 study 161 postmenopausal women with osteoporosis or low bone density received EB613 and demonstrated increases in bone mineral density comparable to those seen with the injectable drug Forteo after six months of treatment. Another candidate EB612 aims to deliver oral parathyroid hormone for hypoparathyroidism a condition that affects approximately two hundred thousand individuals in the United States the European Union and Japan. EB618 is being developed as an oral dual GLP 1 glucagon agonist for obesity and metabolic disorders while an oral GLP 2 peptide targets short bowel syndrome a rare malabsorptive disorder affecting about thirty thousand patients in the United States and the European Union.

Entera Bio Ltd. has not yet generated product sales revenue. The company's current funding comes from research grants collaboration agreements and equity financing. It has received approximately zero point five million dollars in grants from the Israeli Innovation Authority to support its PTH research. Through collaboration agreements with OPKO the company has obtained upfront funding in the form of equity investments such as the eight million dollar share issuance in 2025. These arrangements provide cash to advance research and development while preserving rights to future milestones and royalties. The firm also anticipates potential future revenue from licensing milestones and royalties should its candidates reach commercial approval.

Entera Bio Ltd. operates in a competitive landscape where injectable peptide therapies dominate the market for osteoporosis hypoparathyroidism obesity and gastrointestinal disorders. Key competitors include Eli Lilly with Forteo Amgen with Evenity Radius Health with Tymlos and ApoPharma with teriparatide generics in the osteoporosis space. In hypoparathyroidism the company faces competition from Ascendis Pharma's Yorvipath and other investigational long acting PTH therapies. For obesity the oral GLP 1 glucagon program competes with injectable GLP 1 agonists such as semaglutide and tirzepatide as well as other oral peptide efforts. In short bowel syndrome the only approved therapy is Gattex teduglutide which requires daily subcutaneous injection. Entera Bio Ltd.'s advantage stems from its N Tab technology which enables oral delivery of peptides that traditionally require injection offering potential benefits in patient convenience adherence and reduced healthcare burden. The company's focus on first in class oral candidates seeks to fill treatment gaps where current therapies are burdensome and underutilized.

Entera Bio Ltd. serves patients suffering from osteoporosis hypoparathyroidism obesity and short bowel syndrome as well as the physicians and healthcare providers who treat these conditions. The company also engages with payers and reimbursement agencies that influence access to its future therapies. Collaboration partners such as OPKO provide additional channels for development and potential commercialization. No specific customer names are disclosed in the filing.